Stephen K. Doberstein, SVP & Chief Scientific Officer at NEKTAR THERAPEUTICS (NKTR), bought 30,000 shares at $17.28 ($518K) on 2019-09-05, disclosed to the SEC on 2019-09-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.28 | 15,000 | $259K | 50.0% |
| 2 | $17.28 | 15,000 | $259K | 50.0% |
| Total | $17.28 avg | 30,000 | $518K | 100% |
| Filing → |
| NKTR | SELL | 2019-02-21 | $281K | — | Filing → |
| NKTR | SELL | 2018-11-19 | $173K | — | Filing → |
| NKTR | SELL | 2018-05-18 | $573K | — | Filing → |